17P Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using tri-specific engagers von Miller, J.S., Felices, M., Vallera, D.A., Ettestad, B., Hallstrom, C., Kodal, B., Todhunter, D.A., Arvindam, U.S., Phung, S.K., Kile, Q., Berk, G., Kennedy, P.R.

Volltext